Where Allogene Therapeutics Stands With Analysts
Analysts have provided the following ratings for Allogene Therapeutics (NASDAQ:ALLO) within the last quarter:
Mid-Morning Market Update: Markets Edge Higher; US Economy Adds 194,000 Jobs In September
Following the market opening Friday, the Dow traded up 0.12% to 34,796.95 while the NASDAQ rose 0.09% to 14,667.44. The S&P also rose, gaining 0.16% to 4,406.93.
10 Biggest Price Target Changes For Friday
Barclays cut the price target on Constellation Brands, Inc. (NYSE: STZ) from $260 to $257. Constellation Brands shares fell 0.3% to $215.85 in pre-market trading.
Stifel Downgrades Allogene Therapeutics to Hold
Stifel analyst Benjamin Burnett downgrades Allogene Therapeutics (NASDAQ:ALLO) from Buy to Hold.
The Daily Biotech Pulse: Allogene Sinks On FDA Clinical Hold, Takeda Gets Adcom Backing, Quidel Reports Q3 COVID Revenues, IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Oct. 7)
RBC Capital Maintains Outperform on Allogene Therapeutics, Lowers Price Target to $45
RBC Capital analyst Luca Issi maintains Allogene Therapeutics (NASDAQ:ALLO) with a Outperform and lowers the price target from $55 to $45.